Update on oncolytic viral therapy – targeting angiogenesis

References

• KanedaYTabataYNon-viral vectors for cancer therapyCancer Sci200697534835416630130
   PubMed Web of Science ®Google Scholar
• YoungLSSearlePFOnionDMautnerVViral gene therapy strategies: from basic science to clinical applicationJ Pathol2006208229931816362990
   PubMed Web of Science ®Google Scholar
• HawkinsLKLemoineNRKirnDOncolytic biotherapy: a novel therapeutic plafformLancet Oncol200231172611905600
   PubMed Web of Science ®Google Scholar
• KellyERussellSJHistory of oncolytic viruses: genesis to genetic engineeringMol Ther200715465165917299401
   PubMed Web of Science ®Google Scholar
• KirnDMartuzaRLZwiebelJReplication-selective virotherapy for cancer: biological principles, risk management and future directionsNat Med20017778178711433341
   PubMed Web of Science ®Google Scholar
• LiuTCGalanisEKirnDClinical trial results with oncolytic virotherapy: a century of promise, a decade of progressNat Clin Pract Oncol20074210111717259931
   PubMedGoogle Scholar
• GarberKChina approves world’s first oncolytic virus therapy for cancer treatmentJ Natl Cancer Inst200698529830016507823
   PubMedGoogle Scholar
• HechtJRBedfordRAbbruzzeseJLA phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinomaClin Cancer Res20039255556112576418
   PubMed Web of Science ®Google Scholar
• LiuTCKirnDGene therapy progress and prospects cancer: oncolytic virusesGene Ther2008151287788418418413
   PubMed Web of Science ®Google Scholar
• WongHHLemoineNRWangYOncolytic viruses for cancer therapy: overcoming the obstaclesViruses2010217810620543907
   PubMed Web of Science ®Google Scholar
• SinkovicsJGHorvathJCNewcastle disease virus (NDV): brief history of its oncolytic strainsJ Clin Virol200016111510680736
   PubMed Web of Science ®Google Scholar
• CominsCHeinemannLHarringtonKMelcherADe BonoJPandhaHReovirus: viral therapy for cancer ‘as nature intended’Clin Oncol (R Coll Radiol)200820754855418583112
   PubMed Web of Science ®Google Scholar
• ThorneSHHwangTHO’GormanWERational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963J Clin Invest2007117113350335817965776
   PubMed Web of Science ®Google Scholar
• LiXZhangYPKimHSGene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancerCancer Res20056551941195115753394
   PubMed Web of Science ®Google Scholar
• BissellMJRadiskyDPutting tumours in contextNat Rev Cancer200111465411900251
   PubMed Web of Science ®Google Scholar
• DvorakHFTumors: wounds that do not heal. Similarities between tumor stroma generation and wound healingN Engl J Med198631526165016593537791
   PubMed Web of Science ®Google Scholar
• McKeeTDGrandiPMokWDegradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vectorCancer Res20066652509251316510565
   PubMed Web of Science ®Google Scholar
• ChengJSauthoffHHuangYHuman matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirusMol Ther200715111982199017653103
   PubMed Web of Science ®Google Scholar
• PipiyaTSauthoffHHuangYQHypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expressionGene Ther2005121191191715690061
   PubMed Web of Science ®Google Scholar
• AghiMRabkinSDMartuzaRLAngiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptideCancer Res200767244044417234749
   PubMed Web of Science ®Google Scholar
• KurozumiKHardcastleJThakurREffect of tumor microenvironment modulation on the efficacy of oncolytic virus therapyJ Natl Cancer Inst200799231768178118042934
   PubMedGoogle Scholar
• ChioccaEAThe host response to cancer virotherapyCurr Opin Mol Ther2008101384518228180
   PubMedGoogle Scholar
• ParatoKASengerDForsythPABellJCRecent progress in the battle between oncolytic viruses and tumoursNat Rev Cancer200551296597616294217
   PubMed Web of Science ®Google Scholar
• PrestwichRJHarringtonKJPandhaHSVileRGMelcherAAErringtonFOncolytic viruses: a novel form of immunotherapyExpert Rev Anticancer Ther1020088101581158818925850
   PubMed Web of Science ®Google Scholar
• ShiraishiKKatoSHanSYIsolation of temperature-sensitive p53 mutations from a comprehensive missense mutation libraryJ Biol ChemJan 22004279134835514559903
   PubMed Web of Science ®Google Scholar
• PengZCurrent status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene TherSep200516910161027
   Google Scholar
• MaJHeXWangWE2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancerDig Dis Sci20095471425143119034663
   PubMed Web of Science ®Google Scholar
• OchsenbeinAFPrinciples of tumor immunosurveillance and implications for immunotherapyCancer Gene Ther20029121043105512522443
   PubMed Web of Science ®Google Scholar
• VileRGRussellSJLemoineNRCancer gene therapy: hard lessons and new coursesGene Ther2000712810680008
   PubMed Web of Science ®Google Scholar
• StermanDHRecioACarrollRGA phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responsesClin Cancer Res20071315 Pt 14456446617671130
   PubMed Web of Science ®Google Scholar
• KirnDHWangYLe BoeufFBellJThorneSHTargeting of interferonbeta to produce a specific, multi-mechanistic oncolytic vaccinia virusPLoS Med2007412e35318162040
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med201319332933623396206
   PubMed Web of Science ®Google Scholar
• BreitbachCJBurkeJJonkerDIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansNature201147773629910221886163
   PubMed Web of Science ®Google Scholar
• Pylayeva-GuptaYLeeKEHajduCHMillerGBar-SagiDOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasiaCancer Cell201221683684722698407
   PubMed Web of Science ®Google Scholar
• BayneLJBeattyGLJhalaNTumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancerCancer Cell201221682283522698406
   PubMed Web of Science ®Google Scholar
• GrecoODachsGUGene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectivesJ Cell Physiol20011871223611241346
   PubMed Web of Science ®Google Scholar
• DiasJDLiikanenIGuseKTargeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1Clin Cancer Res20101692540254920388844
   PubMed Web of Science ®Google Scholar
• BraybrookeJPSladeADeplanqueGPhase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanomaClin Cancer Res20051141512152015746054
   PubMed Web of Science ®Google Scholar
• PalmerDHMautnerVMirzaDVirus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancerJ Clin Oncol20042291546155215051757
   PubMed Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• FolkmanJRole of angiogenesis in tumor growth and metastasisSemin Oncol2002296 Suppl 16151812516034
   PubMed Web of Science ®Google Scholar
• LaskinJCrinòLFelipESafety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390)J Thorac Oncol20127120321122173662
   PubMed Web of Science ®Google Scholar
• SobreroAAcklandSClarkeSPhase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancerOncology200977211311919628950
   PubMed Web of Science ®Google Scholar
• TysomeJRLemoineNRWangYCombination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genesCurr Opin Mol Ther200911666466920072943
   PubMed Web of Science ®Google Scholar
• TandleABlazerDGIIILibuttiSKAntiangiogenic gene therapy of cancer: recent developmentsJ Transl Med2004212215219236
   PubMedGoogle Scholar
• DomeBDobosJTovariJCirculating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant diseaseCytometry A200873318619318000872
   PubMed Web of Science ®Google Scholar
• PandyaNMDhallaNSSantaniDDAngiogenesis – a new target for future therapyVascul Pharmacol200644526527416545987
   PubMed Web of Science ®Google Scholar
• MaJWaxmanDJCombination of antiangiogenesis with chemotherapy for more effective cancer treatmentMol Cancer Ther20087123670368419074844
   PubMed Web of Science ®Google Scholar
• SessaCGuibalADel ConteGRüeggCBiomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?Nat Clin Pract Oncol20085737839118560389
   PubMedGoogle Scholar
• Bottsford-MillerJNColemanRLSoodAKResistance and escape from antiangiogenesis therapy: clinical implications and future strategiesJ Clin Oncol201230324026403423008289
   PubMed Web of Science ®Google Scholar
• AlbiniATosettiFLiVWNoonanDMLiWWCancer prevention by targeting angiogenesisNat Rev Clin Oncol20129949850922850752
   PubMed Web of Science ®Google Scholar
• BoehmTFolkmanJBrowderTO’ReillyMSAntiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature199739066584044079389480
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• RelfMLeJeuneSScottPAExpression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesisCancer Res19975759639699041202
   PubMed Web of Science ®Google Scholar
• AngaritaFAAcunaSAOttolino-PerryKZerhouniSMcCartJAMounting a strategic offense: fighting tumor vasculature with oncolytic virusesTrends Mol Med201319637839223540715
   PubMed Web of Science ®Google Scholar
• BreitbachCJDe SilvaNSFallsTJTargeting tumor vasculature with an oncolytic virusMol Ther201119588689421364541
   PubMed Web of Science ®Google Scholar
• BenenciaFCourregesMCConejo-GarciaJROncolytic HSV exerts direct antiangiogenic activity in ovarian carcinomaHum Gene Ther200516676577815960607
   PubMed Web of Science ®Google Scholar
• BreitbachCJArulanandamRDe SilvaNOncolytic vaccinia virus disrupts tumor-associated vasculature in humansCancer Res20137341265127523393196
   PubMed Web of Science ®Google Scholar
• LauKBicknellRAntiangiogenic gene therapyGene Ther19996111793179510602373
   PubMed Web of Science ®Google Scholar
• KirnDHThorneSHTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerNat Rev Cancer200991647119104515
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govUnited States National Institute of Health2013http://www.clinicaltrials.gov/Accessed March 3, 2013
   Google Scholar
• ZhangZZouWWangJSuppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1Mol Ther200511455356215771958
   PubMed Web of Science ®Google Scholar
• ThorneSHTamBYKirnDHContagCHKuoCJSelective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacyMol Ther200613593894616469543
   PubMed Web of Science ®Google Scholar
• XiaoTFanJKHuangHLGuJFLiLYLiuXYVEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosisCell Res201020336737819918267
   PubMed Web of Science ®Google Scholar
• KangYAShinHCYooJYKimJHKimJSYunCONovel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirusMol Ther20081661033104018398429
   PubMed Web of Science ®Google Scholar
• GuseKDiaconuIRajeckiMAd5/3–9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatmentGene Ther20091681009102019440223
   PubMed Web of Science ®Google Scholar
• GuseKSlonieckaMDiaconuIAntiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer modelsJ Virol201084285686619906926
   PubMed Web of Science ®Google Scholar
• OlofssonBKorpelainenEPepperMSVascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cellsProc Natl Acad Sci USA1998952011709117149751730
   PubMed Web of Science ®Google Scholar
• PatilSSGentschevIAdelfingerMVirotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibodyPLoS One2012710e4747223091626
   PubMed Web of Science ®Google Scholar
• GuptaPSuZZLebedevaIVmda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokinePharmacol Ther2006111359662816464504
   PubMed Web of Science ®Google Scholar
• LebedevaIVEmdadLSuZZmda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and anti-angiogenic properties and overview of the phase I clinical experience (Review)Int J Oncol2007315985100717912425
   PubMed Web of Science ®Google Scholar
• FanJKWeiNDingMTargeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 geneInt J Cancer2010127370771719950222
   PubMed Web of Science ®Google Scholar
• XiaoLLWuYMQianJThe antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirusCancer Biol Ther201010324225020574150
   PubMed Web of Science ®Google Scholar
• ChaiLLiuSMaoQA novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapyCancer Gene Ther201219424725422193628
   PubMed Web of Science ®Google Scholar
• XieKInterleukin-8 and human cancer biologyCytokine Growth Factor Rev200112437539111544106
   PubMed Web of Science ®Google Scholar
• YooJYKimJHKimJShort hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibitionGene Ther200815963565118273054
   PubMed Web of Science ®Google Scholar
• CaoRFarneboJKurimotoMCaoYInterleukin-18 acts as an angiogenesis and tumor suppressorFASEB J199913152195220210593867
   PubMed Web of Science ®Google Scholar
• BrundaMJLuistroLWarrierRRAntitumor and antimetastatic activity of interleukin 12 against murine tumorsJ Exp Med19931784122312308104230
   PubMed Web of Science ®Google Scholar
• MaioneTEGrayGSPetroJInhibition of angiogenesis by recombinant human platelet factor-4 and related peptidesScience1990247493877791688470
   PubMed Web of Science ®Google Scholar
• LiuTCZhangTFukuharaHOncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacyMol Ther200614678979717045531
   PubMed Web of Science ®Google Scholar
• VargheseSRabkinSDLiuRNielsenPGIpeTMartuzaRLEnhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancersCancer Gene Ther200613325326516179929
   PubMed Web of Science ®Google Scholar
• WongRJChanMKYuZAngiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12Clin Cancer Res200410134509451615240543
   PubMed Web of Science ®Google Scholar
• MeadowsKNBryantPVincentPAPumigliaKMActivated Ras induces a proangiogenic phenotype in primary endothelial cellsOncogene200423119220014712224
   PubMed Web of Science ®Google Scholar
• LamfersMLGianniDTungCHTissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant gliomaCancer Res200565209398940516230403
   PubMed Web of Science ®Google Scholar
• FolkmanJEndogenous angiogenesis inhibitorsAPMIS20041127–849650715563312
   PubMed Web of Science ®Google Scholar
• LiGShamJYangJPotent antitumor efficacy of an E1B 55 kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinomaInt J Cancer2005113464064815389517
   PubMed Web of Science ®Google Scholar
• LiGCYangJMNieMMPotent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinomaChin Med J (Engl)2005118317918515740644
   PubMed Web of Science ®Google Scholar
• MullenJTDonahueJMChandrasekharSOncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatinCancer2004101486987715305421
   PubMed Web of Science ®Google Scholar
• SuCNaMChenJGene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacyMol Cancer Res20086456857518344493
   PubMed Web of Science ®Google Scholar
• ZhangQNieMShamJEffective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin geneCancer Res200464155390539715289347
   PubMed Web of Science ®Google Scholar
• PanJGZhouXZengGWHanRFPotent antitumour activity of the combination of HSV-TK and endostatin armed oncolytic adeno-associated virus for bladder cancer in vitro and in vivoJ Surg Oncol2012105324925721953122
   PubMed Web of Science ®Google Scholar
• GoodwinJMSchmittADMcGinnCMAngiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer modelCancer Invest201230324325022360364
   PubMed Web of Science ®Google Scholar
• YangLWangLSuXQSuppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatinCancer Gene Ther2010171495719609295
   PubMed Web of Science ®Google Scholar
• ZhangWFulciGBuhrmanJSBevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 gliomaMol Ther2012201374521915104
   PubMed Web of Science ®Google Scholar
• ScappaticciFAContrerasASmithRStatin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activityAngiogenesis20014426326812197471
   PubMedGoogle Scholar
• LiXLiuYHLeeSJGardnerTAJengMHKaoCProstate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacyClin Cancer Res200814129129918172281
   PubMed Web of Science ®Google Scholar
• YangCTLinYCLinCLOncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cellsAnticancer Res2005253B2049205416158944
   PubMed Web of Science ®Google Scholar
• TysomeJRBriatAAlusiGLister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancerGene Ther200916101223123319587709
   PubMed Web of Science ®Google Scholar
• TysomeJRWangPAlusiGLister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancerHum Gene Ther20112291101110821361787
   PubMed Web of Science ®Google Scholar
• CaoYChenAAnSSJiRWDavidsonDLlinásMKringle 5 of plasminogen is a novel inhibitor of endothelial cell growthJ Biol Chem19972723622924229289278456
   PubMed Web of Science ®Google Scholar
• FanJKXiaoTGuJFIncreased suppression of oncolytic adenovirus carrying mutant k5 on colorectal tumorBiochem Biophys Res Commun2008374219820318621025
   PubMed Web of Science ®Google Scholar
• HeXPSuCQWangXHE1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancerCancer Lett20092851899819481338
   PubMed Web of Science ®Google Scholar
• HardcastleJKurozumiKDmitrievaNEnhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1Mol Ther201018228529419844198
   PubMed Web of Science ®Google Scholar
• LiuTCZhangTFukuharaHDominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumorsClin Cancer Res200612226791679917121900
   PubMed Web of Science ®Google Scholar
• JainRKFinnAVKolodgieFDGoldHKVirmaniRAntiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilizationNat Clin Pract Cardiovasc Med20074949150217712362
   PubMedGoogle Scholar